Smallpox vaccine enters Phase 3 Trial
by Press Release from Outbreak News Today on (#4HHND)
Bavarian Nordic A/S announced today the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN(R) smallpox vaccine in 1,110 healthy, vaccinia-naive subjects. The randomized, double-blind, multicenter trial will evaluate the immunogenicity and safety of three consecutive vaccine lots of the freeze-dried formulation of MVA-BN(R)smallpox vaccine, similar to the prior completed Phase 3 ["]
The post Smallpox vaccine enters Phase 3 Trial appeared first on Outbreak News Today.